



Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA)

SCIENTIFIC COMMITTEE MEMBERS AND EXPERTS

I, Robin Vos

Organisation/Company: N/A

Country: Belgium

Declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical companies and in medical device companies are those listed below:

Pharmaceutical company interests

1.1 Employment

No interest declared

1.2 Consultancy

Time Period	Start Date	End Date	Name of pharmaceutical company	Type	Product name	Therapeutic indication	General role / Area of activity
Past	01-05-2021	01-05-2021	Takeda	Individual product related	Maribavir	CMV infection in Solid Organ Transplantation	
Past	01-01-2022	31-01-2022	GSK	Cross product related/ general (non product related)			COVID-19 drugs and vaccines
Past	01-01-2023	01-03-2024	Takeda	Individual product related	Maribavir	CMV infection	
Current	01-04-2023		Zambon	Cross product related/ general (non product related)			BOS after lung transplantation
Past	01-12-2023	01-12-2023	Shionogi	Individual product related	Orolofim	Fungal infections	
Past	01-11-2022	30-11-2022	Natera	Cross product related/ general (non product related)			ddcfDNA in lung transplantation
Past	01-06-2022	01-06-2022	AstraZeneca	Individual product related	Evusheld	COVID_19	
Current	01-01-2023		GSK	Cross product related/ general (non product related)			RSV Vaccines
Past	01-11-2017	01-11-2017	Shire	Individual product related	Maribavir	CMV infection in Solid Organ Transplantation	

1.3 Strategic advisory role

No interest declared

1.4 Financial interests

Name of pharmaceutical company	Financial interest	Other comments
AstraZeneca	Compensation/Fees/Honoraria/etc.	Honoraria for consultancy activity (2022)
Shionogi	Compensation/Fees/Honoraria/etc.	Honoraria for consultancy activity (2023)
Takeda	Compensation/Fees/Honoraria/etc.	Honoraria for consultancy activity (2021 and 2023)
GSK	Compensation/Fees/Honoraria/etc.	Honoraria for consultancy activity (2022 and 2023)
Shire	Compensation/Fees/Honoraria/etc.	Honoraria for consultancy activity (2017)

1.5 Principal investigator

No interest declared

1.6 Investigator

Time Period	Start Date	End Date	Name of pharmaceutical company	Product Name	Therapeutic indication
Current	01-06-2020		Incyte	Itacitinib	Bronchiolitis Obliterans Syndrome after lung transplantation
Current	01-12-2020		ZAMBON and BREATHE Therapeutics	Liposomal Cyclosporine_A	Bronchiolitis Obliterans Syndrome after lung transplantation
Current	01-10-2023		Sanofi	Belumosetil	Bronchiolitis Obliterans Syndrome after lung transplantation

1.7 Grant / Funding to organisation /institution

Name of pharmaceutical company	Subject Matter
AstraZeneca	Research award Belgian Respiratory Society (2019)
Astellas	Research grant (2019 + 2020)
Sandoz	Research grant (2019)
Roche	Research award Belgian Transplant Society (2019)
AstraZeneca	Research Grant (2024)

1.8 Close family member interest

No interest declared

1.9 Repurposing of a medicinal product

No interest declared

1.10 Any other interests or facts

- Academic trials:
-Principal Investigator: NCT01915082/AZI003, 2020-001614-38/DAWn-AZITHRO
-Sub/Co-Investigator: NCT01009619/AZI001, NCT01109160/AZI002, NCT01212406/VIT001, NCT01211509/MLK, NCT02262299/EPOS, NCT04122768/Coaching, NCT04579471/COVITRA

I work in an organisation/institution where my colleagues provide consultancy advice to pharmaceutical companies, but I am currently not directly involved in the provision of such advice.

I am member of the European Respiratory Society (ERS) (2007-present), European Society for Organ Transplantation (ESOT)(2016_present), International Society for Heart and Lung Transplantation (ISHLT) (2007-present), Belgian Respiratory Society (BeRS) (2007-present) and Belgian Transplant Society (BTS) (2012-present), which which may be funded in part from restricted or unrestricted grants from pharmaceutical companies (not from one single company), of which I am not involved in,

nor benefit from.

My Institution receives research funds from the Research Foundation Flanders (FWO) for my academic work.

1.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

Medical device company interests

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

No interest declared

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Any other interests or facts

No interest declared

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information

or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party ¹ any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to indicate clearly that the views are my own if acting in my own capacity or those of the EMA, Management Board, Committee, Working Party, Expert Group or other group if acting on behalf of that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate and complete to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

1. Third party does not include employees of the National Competent Authorities who either have employment contracts that provide confidentiality obligations or are encompassed by confidentiality obligations under national legislation on professional secrecy.

Full Name:	Robin Vos
Date:	2024-07-01

For definitions of activities etc, refer to the policy on handling of competing interests.